- Home
- CCEC vs CAPR Comparison
CCEC vs CAPR Comparison
Compare CCEC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- CAPR
- Stock Information
- Founded
- CCEC 2007
- CAPR 2005
- Country
- CCEC Greece
- CAPR United States
- Employees
- CCEC N/A
- CAPR N/A
- Industry
- CCEC Marine Transportation
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCEC Consumer Discretionary
- CAPR Health Care
- Exchange
- CCEC Nasdaq
- CAPR Nasdaq
- Market Cap
- CCEC 1.1B
- CAPR 867.6M
- IPO Year
- CCEC 2007
- CAPR N/A
- Fundamental
- Price
- CCEC $18.32
- CAPR $12.73
- Analyst Decision
- CCEC Buy
- CAPR Strong Buy
- Analyst Count
- CCEC 1
- CAPR 7
- Target Price
- CCEC $22.00
- CAPR $39.29
- AVG Volume (30 Days)
- CCEC 16.9K
- CAPR 1.5M
- Earning Date
- CCEC 01-31-2025
- CAPR 11-13-2024
- Dividend Yield
- CCEC 3.29%
- CAPR N/A
- EPS Growth
- CCEC N/A
- CAPR N/A
- EPS
- CCEC 0.85
- CAPR N/A
- Revenue
- CCEC $447,305,000.00
- CAPR $23,228,045.00
- Revenue This Year
- CCEC N/A
- CAPR N/A
- Revenue Next Year
- CCEC N/A
- CAPR $74.85
- P/E Ratio
- CCEC $73.15
- CAPR N/A
- Revenue Growth
- CCEC 29.66
- CAPR 65.33
- 52 Week Low
- CCEC $13.41
- CAPR $3.52
- 52 Week High
- CCEC $20.26
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- CAPR 37.54
- Support Level
- CCEC N/A
- CAPR $13.00
- Resistance Level
- CCEC N/A
- CAPR $20.75
- Average True Range (ATR)
- CCEC 0.00
- CAPR 1.60
- MACD
- CCEC 0.00
- CAPR -0.30
- Stochastic Oscillator
- CCEC 0.00
- CAPR 11.04
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.